| abstract |
The present invention relates to a cannabinoid type 2 receptor affinity pharmaceutical composition. The compound is represented by the following formula (I):n n n [Formula I]n n n n n n n n [In the meal,n n n R 1 is of the formula -Y 1 -Y 2 -Y 3 -R a , wherein Y 1 is a single bond or the like; Y 2 is -C (= O) -NH- or the like; Y 3 is an optionally substituted aryl or the like; Groups represented;n n n R 2 is hydrogen or the like;n n n R 3 is alkyl or the like;n n n R 4 is alkyl or the like;n n n R 5 is optionally substituted alkyl or the like;n n n R 3 and R 4 form an adjacent atom with a ring group and the like). |